Open Collections

UBC Faculty Research and Publications

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer Tischkowitz, Marc; Brunet, Jean-Sébastien; Bégin, Louis R.; Huntsman, David G.; Cheang, Maggie C.; Akslen, Lars A.; Nielsen, Torsten; Foulkes, William D.

Abstract

Background: Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested. Methods Using datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP). Results There was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p

Item Metadata

Title
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Creator
Tischkowitz, Marc; Brunet, Jean-Sébastien; Bégin, Louis R.; Huntsman, David G.; Cheang, Maggie C.; Akslen, Lars A.; Nielsen, Torsten; Foulkes, William D.
Publisher
BioMed Central
Date Issued
2007-07-24
Description
Background: Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested. Methods Using datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP). Results There was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p
Genre
Article
Type
Text
Language
eng
Date Available
2015-12-09
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0220861
URI
http://hdl.handle.net/2429/55735
Affiliation
Other UBC; Non UBC
Citation
BMC Cancer. 2007 Jul 24;7(1):134
Publisher DOI
10.1186/1471-2407-7-134
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
Tischkowitz et al.
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)